Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching ...

JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of ...

Stifel initiated coverage of Ligand (LGND) with a Buy rating and $143 price target Ligand, which provides “an important source of differentiated capital” through royalty-financing deals to mid ...

(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp.(CHRO) to combine Ligand's wholly owned subsidiaries, Pelthos ...

Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin ...